Obesity and serial nt-probnp levels in guided medical therapy for heart failure with reduced ejection fraction: Insights from the guide-it trial

Vibhu Parcha, Nirav Patel, Rajat Kalra, Sarabjeet S. Suri, Garima Arora, Thomas J. Wang, Pankaj Arora

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


BACKGROUND: Obese patients have lower NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels. The prognostic implications of achieving NT-proBNP levels ≤1000 pg/mL in obese patients with heart failure (HF) receiving biomarker-guided therapy are not completely known. We evaluated the prognostic implications of obesity and having NT-proBNP levels (≤1000 pg/ mL) in the GUIDE-IT (Guiding Evidence-Based Therapy Using Biomarker-Intensified Treatment in HF) trial participants. METHODS AND RESULTS: The risk of adverse cardiovascular events (HF hospitalization or cardiovascular mortality) was assessed using multivariable-adjusted Cox proportional hazard models based on having NT-proBNP ≤1000 pg/mL (taken as a time-varying covariate), stratified by obesity status. The study outcome was also assessed on the basis of the body mass index at baseline. The predictive ability of NT-proBNP for adverse cardiovascular events was assessed using the likelihood ratio test. Compared with nonobese patients, obese patients were mostly younger, Black race, and more likely to be women. NT-proBNP levels were 59.0% (95% CI, 39.5%–83.5%) lower among obese individuals. The risk of adverse cardiovascular events was lower in obese (hazard ratio [HR], 0.48; 95% CI, 0.29–0.59) and nonobese (HR, 0.32; 95% CI, 0.19–0.57) patients with HF who had NT-proBNP levels ≤1000 pg/mL, compared with those who did not. There was no interaction between obesity and having NT-proBNP ≤1000 pg/mL on the study outcome (P>0.10). Obese patients had a greater risk of developing adverse cardiovascular events (HR, 1.39; 95% CI, 1.01–1.90) compared with nonobese patients. NT-proBNP was the strongest predictor of adverse cardiovascular event risk in both obese and nonobese patients. CONCLUSIONS: On-treatment NT-proBNP level ≤1000 pg/mL has favorable prognostic implications, irrespective of obesity status. NT-proBNP levels were the strongest predictor of cardiovascular events in both obese and nonobese individuals in this trial. REGISTRATION: URL: https://www.clini​caltr​ials.gov; Unique identifier: NCT01685840.

Original languageEnglish (US)
Article numbere018689
JournalJournal of the American Heart Association
Issue number7
StatePublished - 2021


  • Cardiovascular outcomes
  • Heart failure
  • Mortality
  • Natriuretic peptides
  • Obesity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Obesity and serial nt-probnp levels in guided medical therapy for heart failure with reduced ejection fraction: Insights from the guide-it trial'. Together they form a unique fingerprint.

Cite this